For results for completed and on-going clinical trials in ovarian cancer for all drugs in a specific category, click on the drug category (e.g., Angiogenesis Inhibitors) on the left. To see only results for specific drugs in a class, click on the drug class for the drugs that interest you. For a schematic diagram of cell growth and survival pathways that these drugs inhibit, please scroll to the bottom of the page.

DNA DAMAGE REPAIR PATHWAY INHIBITORS PARP Inhibitors Niraparib (Zejula™)
Olaparib (Lynparza™)
Pamiparib
Rucaparib (Rubraca™)
Talazoparib (Talzenna™)
Veliparib
ATR Inhibitors Berzosertib
ANTIBODY TARGETED DRUG CONJUGATES Antibody Drug Conjugates (ADC)

Targeting Mesothelin, CD166, MUC16, Axl, FRalpha,
Tissue Factor, NaPi2b

Anetumab ravtansine
Praluzatamab ravtansine
DMUC4064A
Enapotamab vedotin
Mirvetuximab soravtansine
STRO-002
Tisotumab vedotin
Upifitamab rilsodotin (XMT-1536)
ANGIOGENESIS and GROWTH FACTOR/ RECEPTOR INHIBITORS VEGF, DLL4 Antagonists Bevacizumab (Avastin™)
Dilpacimab
Navicixizumab
VEGFR Inhibitors Cediranib
Multi-targeted RTK Inhibitors Lenvatinib (Lenvima™)
Pazopanib (Votrient™)
Rebastinib
Sitravatinib
Sorafenib
Gas6 Antagonists AVB-S6-500
HORMONAL  THERAPY Aromatase Inhibitors Anastrozole (Arimidex™)
Letrozole (Femara™)
Anti Estrogens Tamoxifen (Nolvadex™)
GR Antagonists Relacorilant
SIGNALING PATHWAY INHIBITORS Integrins/FAK Pathway

Targeting FAK

Defactinib
PI3K/AKT/mTOR Pathway

Targeting AKT, PI3Kalpha, pan-PI3K, mTOR, TORC1/2

Afuresertib
Alpelisib (Piqray™)
Buparlisib
Everolimus (Afinitor™)
Temsirolimus (Torisel™)
Vistusertib
Metformin
RAS/RAF/MAPK Pathway

Targeting RAF, MEK

Binimetinib (Mektovi™)
Selumetinib (Koselugo™)
Trametinib (Mekinist™)
VS-6766
JAK/STAT Pathway
Targeting Stat3
Napabucasin
CELL CYCLE INHIBITORS AURK Inhibitors Alisertib
CDK4/6 Inhibitors Palbociclib (Ibrance™)
Ribociclib (Kisqali™)
CHK1/2 Inhibitors Prexasertib
p53 Activators Eprenetapopt
Wee1 Inhibitors Adavosertib
IMMUNOTHERAPY Anti-Tumor Antibodies

Targeting CA125

Oregovomab
Bispecific Antibodies

Targeting PD-1/LAG-3

Tebotelimab
Cellular Therapy

Targeting MUC16Ecto

4H11-28z/fIL-12/EFGRt+ CAR T
Checkpoint Inhibitors

Targeting CD47, CTLA-4, PD-1, PD-L1

Atezolizumab (Tecentriq™)
Avelumab (Bavencio™)
Dostarlimab (Jemperli™)
Durvalumab (Imfinzi™)
Ipilimumab (Yervoy™)
Magrolimab
Nivolumab (Opdivo™)
Pembrolizumab (Keytruda™)
Tislelizumab
Tremelimumab
Immune Cell Stimulators

Targeting IDO

Epacadostat
Vaccines

Targeting Tumor-associated Antigens, Survivin, TGFbeta, NY-ESO-1

DCVAC/OvCa
Maveropepimut-S (DPX-Survivac)
Gemogenovatucel-T (FANG/Vigil™)
NY-ESO-1
ONCOLYTIC VIRUSES Oncolytic Viruses MV-NIS
Olvimulogene Nanivacirepvec (GL-ONC-1)

This diagram shows some of the key cell signaling pathways that are affected by genetic mutations or alterations found in ovarian cancers. The names of proteins encoded by the genes involved in various steps of each pathway are shown. Some proteins promote (indicated by an arrow) a particular step in the pathway and spur cell growth. Other proteins inhibit (indicated by the perpendicular symbol) a step in the pathway and prevent cells from growing and dividing in an uncontrolled way. Some genetic mutations/alterations result in a protein that is more active than it would normally be (shown in green), while others cause the protein to be less active (shown in red). A more active protein that stimulates cell growth or decreased activity of a protein that inhibits these processes can both lead to the uncontrolled growth seen in cancers.